key: cord-0748185-0qocfhn5
authors: Kohler, Philipp; Jonsdottir, Hulda R.; Risch, Lorenz; Vernazza, Pietro; Ackermann-Gäumann, Rahel; Kahlert, Christian R.
title: No neutralizing effect of pre-existing tick-borne encephalitis virus antibodies against severe acute respiratory syndrome coronavirus-2: a prospective healthcare worker study
date: 2021-12-17
journal: Sci Rep
DOI: 10.1038/s41598-021-03685-y
sha: 166d85438657a5a03623eadb18d09b7a707be09e
doc_id: 748185
cord_uid: 0qocfhn5

Certain immunizations including vaccination against tick-borne encephalitis virus (TBEV) have been suggested to confer cross-protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Within a prospective healthcare worker (HCW) cohort, we assessed the potentially protective role of anti-TBEV antibodies against SARS-CoV-2 infection. Among 3352 HCW, those with ≥ 1 previous TBEV vaccination (n = 2018, 60%) showed a reduced risk of SARS-CoV-2 seroconversion (adjusted odds ratio: 0.8, 95% CI: 0.7–1.0, P = 0.02). However, laboratory testing of a subgroup of 26 baseline and follow-up samples did not demonstrate any neutralizing effect of anti-TBEV antibodies against SARS-CoV-2 in live-virus neutralization assay. However, we observed significantly higher anti-TBEV antibody titers in follow-up samples of participants with previous TBEV vaccination compared to baseline, both TBEV neutralizing (p = 0.001) and total IgG (P < 0.0001), irrespective of SARS-CoV-2 serostatus. Based on these data, we conclude that the observed association of previous TBEV vaccination and reduced risk of SARS-CoV-2 infection is likely due to residual confounding factors. The increase in TBEV follow-up antibody titers can be explained by natural TBEV exposure or potential non-specific immune activation upon exposure to various pathogens, including SARS-CoV-2. We believe that these findings, although negative, contribute to the current knowledge on potential cross-immunity against SARS-CoV-2 from previous immunizations.

| (2021) 11:24198 | https://doi.org/10.1038/s41598-021-03685-y www.nature.com/scientificreports/ Another intriguing hypothesis is that pre-existing immunity against other pathogens might confer a partial resistance to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several candidates have been proposed, including previous exposure to endemic coronaviruses 3 , malaria 4 , seasonal influenza 5 , Bacillus Camille-Guerin vaccination 6 , measles vaccination 7 , and flaviviruses 8 . Data from Brazil show that geographic regions with high dengue virus (DENV) burden have reported fewer COVID-19 cases 9 and COVID-19 patients previously infected with DENV had a lower case fatality rate compared to those without previous infection 8 . Furthermore, structural similarities between SARS-CoV-2 and DENV leading to potential antigenic cross-reactivity have been postulated 10 . Other members of the flaviviridae family include Japanese encephalitis virus (JEV) and tick-borne encephalitis virus (TBEV) and it has been hypothesized that differential burden of COVID-19 could-at least partly-be attributable to different national vaccination strategies for JEV (in Asian countries) and TBEV (in European countries) 11 .

Combined, these findings prompted us to investigate any potential cross-immunity against SARS-CoV-2 mediated by anti-TBEV antibodies. First, we assessed the association between self-reported TBEV vaccination and SARS-CoV-2 seropositivity within a large prospective healthcare worker (HCW) study. Second, we analysed baseline and follow-up samples from HCW to evaluate whether anti-TBEV antibodies showed any cross-neutralizing effect against SARS-CoV-2 and whether SARS-CoV-2 infection could increase titers of preexisting anti-TBEV antibodies.

Previous TBEV vaccination and SARS-CoV-2 seroconversion. The HCW cohort included 3352 individuals, whereof 633 (19%) had positive SARS-CoV-2 serology. Among these 633, 352 (56%) reported a previous TBEV vaccination compared to 1666 (61%) out of 2719 with a negative SARS-CoV-2 serology. Previous TBEV vaccination was therefore associated with decreased risk of SARS-CoV-2 seroconversion with an odds ratio (OR) of 0.8 and a 95% confidence interval (CI) of 0.7-0.9 (P = 0.009). After adjusting for predefined variables, the association remained unchanged with an adjusted OR (aOR) of 0.8; 95% CI 0.7-1.0 (P = 0.02, Table 1) .

No cross-neutralization of TBEV antibodies against SARS-CoV-2. We analysed 26 baseline (T1, March/April 2020) and follow-up (T2, August/September 2020) samples divided into three groups defined above. Group characteristics are summarized in Table 2 .

As expected, all four individuals in group 1 had neutralizing antibodies against SARS-CoV-2 in their followup (T2), but not in their baseline (T1) sample (Fig. 1a, blue) . However, none of the sera from group 2 exhibited any cross-neutralization against SARS-CoV-2 (Fig. 1a, black) . Thus, anti-TBEV-antibodies did not have any direct neutralizing effect on SARS-CoV-2 in these samples. Additionally, all four individuals (100%) from group 1 and 16/17 individuals (94%) from group 2 had neutralizing antibodies against TBEV in both baseline and follow-up www.nature.com/scientificreports/ samples, except for one individual from group 2 who tested negative at T1 but positive at T2. Within the control (group 3), four individuals tested negative for neutralizing antibodies against TBEV as expected, whereas one tested positive at both T1 and T2 (Fig. 1b, red) . As individuals were assigned to groups based on their vaccination history, this person is likely to have acquired anti-TBEV antibodies naturally. Overall, neutralizing TBEV antibody titers were significantly higher in the follow-up samples (T2) than in the baseline samples (T1) (P < 0.0001). However, this trend was observed in both groups 1 and 2, therefore these results do not allow for any conclusions about a triggered TBEV antibody response due to a recent SARS-CoV-2 infection. Furthermore, an increase in TBEV neutralizing antibody titer was only observed in 50% of positive samples (11/22).

TBEV-IgG ELISA are in agreement with the observed serum neutralization test (SNT) results. As observed for neutralizing TBEV antibody titers, anti-TBEV IgG titers determined by ELISA were significantly higher in the follow-up samples (T2, higher titer in 16 of 22 samples) than in the baseline samples (T1), (P < 0.0001), again irrespective of SARS-CoV-2 serostatus (Fig. 2a) . For IgM, we observed a trend towards decreasing antibody titers from T1 to T2 for all but two samples. For these two samples (one each within groups 1 and 2), IgM seroconversion was observed, however at low titers (Fig. 2b) .

In the current study, we found an association between previous TBEV vaccination and decreased rates of SARS-CoV-2 seroconversion within a prospective cohort of Swiss HCWs. The observed association could not be explained by any cross-neutralizing effect of anti-TBEV antibodies on SARS-CoV-2. Unexpectedly, anti-TBEV antibody titers increased overall between baseline and follow-up samples, irrespective of SARS-CoV-2 seroconversion, albeit not in all samples. The hypothesis that pre-existing TBEV antibodies might confer cross-immunity against SARS-CoV-2 is intriguing, particularly given the availability of an effective TBEV vaccine. However, we could not explain this observation by characterizing the humoral adaptive immune response against TBEV and SARS-CoV-2, as there was no cross-neutralizing effect of anti-TBEV antibodies against SARS-CoV-2 or vice versa. Our findings are in agreement with former studies demonstrating that antibodies cross-neutralizing SARS-CoV-2 are rare [12] [13] [14] [15] [16] and that cross-reactive immune memory appears limited largely to CD4 + T cells 17 . As our cohort is limited to serum samples, aspects of cellular immunity could not be studied in this population. We therefore assume that the observed effect might be due to confounding factors. For instance, since vaccination against TBEV is optional in Switzerland, HCW who choose this vaccination might be more health conscious However, a growing body of literature supports the premise of innate immune memory. The concept of trained immunity describes the long-term functional reprogramming of innate immune cells leading to an altered response towards a second challenge after return to a non-activated state 21 . It has been postulated that trained immunity induced by the bacillus Calmette Guerin (BCG, tuberculosis vaccine) adjuvants could confer protection against SARS-CoV-2 6, 22, 23 . Also, previous vaccination against pneumococci is associated with decreased risk of SARS-CoV-2 acquisition 24 . Since, as observed here for TBEV, anti-pneumococcal antibodies do not have a direct neutralising effect on SARS-CoV-2, non-specific activation of the immune system has been suspected, which is in accordance with the concept of trained immunity. Further supporting this hypothesis, other recent non-COVID-19 vaccinations (including polio, varicella, measles-mumps-rubella, seasonal influenza and others) have also been associated with a decreased risk for SARS-CoV-2 infection 25 . However, for immunity against the fusion protein of the measles virus, some evidence of cross-reaction with the receptor binding domain of SARS-CoV-2 has been proposed 25 . Interestingly, both neutralizing capacity and IgG antibody titers against TBEV increased between baseline and follow-up samples for most HCW, irrespective of SARS-CoV-2 seroconversion. A possible explanation is that these people were exposed to TBEV naturally as the study period included spring and summer. We also hypothesized that exposure to SARS-CoV-2 and other pathogens had a potential boosting effect on TBEV titers. However, a post-hoc analysis of our data found no correlation between patient contact and up-regulation of TBEV antibodies, making this scenario less likely.

The dual methodological approach used in this study provides a unique insight into a large cohort of HCW exposed to COVID-19. Furthermore, the large sample size and prospective nature of this HCW cohort allowed us to correct for important co-variables. However, limitations include that previous TBEV vaccination was nondated and self-reported and, as previously stated, that only the humoral but not the cellular immune response could be characterized. Also, the relatively small number of sera analysed for the presence of both SARS-CoV-2 and TBEV antibodies is a significant limitation of the study.

In conclusion, we found an association between previous TBEV vaccination and reduced seroconversion rates of anti-SARS-CoV-2 antibodies among a cohort of Swiss HCW. This observation could not be explained by characterizing the humoral adaptive immune response against either TBEV or SARS-CoV-2, as there was no cross-neutralizing effect of anti-TBEV antibodies against SARS-CoV-2 or vice versa. Although residual confounding is the most likely explanation, trained immunity, i.e., non-specific activation of the innate immune system conferring protection against heterologous infections, could also account for this finding although we did not observe a correlation to patient contact in this study. Since the beginning of the pandemic, many publications www.nature.com/scientificreports/ have hypothesized about potential cross-immunity against SARS-CoV-2 and despite the negative results reported here, we believe it is important to experimentally investigate such claims to separate facts from hypotheses.

Study design and sample sources. We analysed data from a prospective HCW cohort comprising 3352 participants from Northern and Eastern Switzerland 26 . In January and February 2021, participants were asked about previous vaccinations against TBEV (at least one) via online questionnaire. At the same time, venous blood samples were taken and analysed regarding the presence of anti-SARS-CoV-2 (anti-nucleocapsid) antibodies, using an electro-chemiluminescence immunoassay (ECLIA, Roche Diagnostics, Basel, Switzerland), as previously described 27 . Additionally, we analysed a convenience sample of baseline and follow-up sera from a precursor study of the above-mentioned cohort 28 , where participants had already provided baseline (March/April 2020, time point T1) and follow-up (August/September 2020, time point T2) blood samples. Blood samples were tested for the presence of anti-SARS-CoV-2 (anti-nucleocapsid) antibodies with the same ECLIA as previously described. For the laboratory analysis, three HCW groups were pre-defined: (i) HCW vaccinated against TBEV with seroconversion for SARS-CoV-2 between baseline and follow-up (group 1, n = 4); (ii) HCW vaccinated against TBEV without seroconversion for SARS-CoV-2 (group 2, n = 17); and (iii) HCW not vaccinated against TBEV without seroconversion and without positive PCR for SARS-CoV-2 (group 3, n = 5). Electronic informed consent was obtained from all study participants. The study was approved by the ethics committee of Eastern Switzerland (#2020-00,502), an institution of the health departments of the participating cantons (i.e. districts).

All research was performed according to the relevant guidelines and regulations.

To assess the presence of neutralizing antibodies against SARS- TBEV ELISA. Sera were tested with SERION ELISA classic FSME Virus/TBE Virus IgG and IgM kits (Viri-onSerion GmbH, Würzburg, Germany). Analyses were performed manually according to the manufacturer's instructions. Antibody titers (U/ml) were calculated with the following cut-offs: IgG negative < 100 U/ml, equivocal 100-150 U/ml, positive > 150 U/ml; IgM negative < 10 U/ml, equivocal 10-15 U/ml, positive > 15 U/ml).

For the association between previous TBEV vaccination and positive SARS-CoV-2 serology, we used univariable and multivariable logistic regression. The following pre-defined variables were entered into the model: age, sex, profession (categories: nurse, physician, other), and patient contact (yes or no). SPSS statistical software, version 20.0 (IBM, Armonk, New York, USA) was used for the association analysis. For the comparison of antibody titers between baseline and follow-up sera, Wilcoxon matched-pairs signed rank test was applied using GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego, California USA www. graph pad. com). P-values < 0.05 were considered statistically significant.

Data are available from the authors upon reasonable request. www.nature.com/scientificreports/ Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.

What could explain the late emergence of COVID-19 in Africa

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19

SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt

Influenza vaccination and COVID19 mortality in the USA

BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)

Vaccine repurposing approach for preventing COVID 19: Can MMR vaccines reduce morbidity and mortality?

Previous dengue infection and mortality in coronavirus disease 2019 (COVID-19)

How super-spreader cities, highways, hospital bed availability, and dengue fever influenced the COVID-19 epidemic in Brazil

Potential antigenic cross-reactivity between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and dengue viruses

Cross-protection induced by encephalitis vaccines against COVID-19 might be a reason for relatively lower mortality rate in some countries

Rapid generation of neutralizing antibody responses in COVID-19 patients

A serological assay to detect SARS-CoV-2 seroconversion in humans

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike proteinprotein interaction

Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Cross-reactive memory T cells and herd immunity to SARS-CoV-2

Indoor transmission of SARS-CoV-2

Outdoor transmission of SARS-CoV-2 and other respiratory viruses: A systematic review

Simple quantitative assessment of the outdoor versus indoor airborne transmission of viruses and covid-19

Defining trained immunity and its role in health and disease

Acute lower respiratory infection among Bacille Calmette-Guérin (BCG)-vaccinated children

Trained innate immunity, epigenetics, and Covid-19

BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers

Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations

Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers-A multicentre cross-sectional study

Characteristics of three different chemiluminescence assays for testing for SARS-CoV-2 antibodies. Dis. Markers. 2021, 8810196

Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study

This work was supported by the Swiss National Science Foundation (Grant number 31CA30_196544; Grant number PZ00P3_179919 to PK), the Federal Office of Public Health (Grant number 20.008218/421-28/1), and the Health Department of the Canton of St. Gallen. We would like to thank the laboratory staff for shipment, handling, and analysis of blood samples. In particular, we acknowledge the core study team; Simone Kessler, Thomas Egger, and Susanne Nigg, without whom this study would not have been possible.

P.K., H.R.J., R.A. and C.K. were responsible for study design and conceptualization. P.K. and C.K. provided patient data. H.R.J., L.R. and R.A. performed the laboratory analyses. P.K. analysed the epidemiological data. H.R.J. analysed data and prepared the figures. P.K., P.V. and C.K. were responsible for study funding. P.K. and H.R.J. drafted the first version of the manuscript. All authors contributed to and critically revised the manuscript.

The authors declare no competing interests.

Correspondence and requests for materials should be addressed to P.K.Reprints and permissions information is available at www.nature.com/reprints.